MASS News and Press, 908 Devices Inc. From 01/27/23

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...

MAVEN offers real-time monitoring without bioreactor volume loss, accelerating process development and optimizing biologics, cell therapy and gene therapy manufacturing 908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, ...

Customers, including the Minnesota Department of Corrections, are leveraging the MX908 handheld device to keep correctional officers and inmates safe from drug exposure and prevent overdoses 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec d...

908 Devices Inc. (MASS) Q3 2022 Results Conference Call November 14, 2022 08:30 AM ET Company Participants Kelly Gura - IR Kevin Knopp - CEO and Co-Founder Joe Griffith - CFO Conference Call Participants Max Masucci - Cowen Daniel Arias - Stifel ...

Shares of 908 Devices (NASDAQ: MASS) were down 19% as of 11 a.m. ET on Monday. The steep decline came after the maker of handheld and desktop mass spec devices for chemical and biomolecular analysis announced its third-quarter results earlier in the morning. 908 Devices reported...

908 Devices press release ( NASDAQ: MASS ): Q3 GAAP EPS of -$0.20 beats by $0.02 . Revenue of $15.8M (+25.9% Y/Y) beats by $0.11M . 908 Devices is updating its full year 2022 revenue outlook and now expects revenue to be in the range of $46 million to $49 milli...

Q3 2022 revenue increases 26% over prior year, with gross margin of 59% 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended September...

Driven by Biopharma 4.0, proteomics research and acquisition of TRACE Analytics, 908 Devices empowers more effective drug discoveries 908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, con...

Developed in coordination with the U.S. Forest Service, the MX908 can identify toxic pesticides that pose threats to wildlife, water sources and communities 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical an...

908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the third quarter 2022 before market open on Monday, November 14, 2022. Company management will...